Corrigendum: Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

Affiliations

• ¹ Hainan Hospital of PLA General Hospital, Department of General Surgery, Haitang District, Sanya, China.
• ² Department of Clinical Laboratory, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
• ³ Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
• ⁴ Pancreas Center of Guangdong Provincial People's Hospital, Guangzhou, China.
• ⁵ Department of Spine Surgery, The Second Affiliated Hospital, Shantou University Medical College, Shantou, China.
• ⁶ Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Center, Guangzhou, China.